# S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

> **NCT00945815** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 35 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** epratuzumab
- **DRUG:** clofarabine
- **DRUG:** cytarabine
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00945815
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-03
- **Final completion:** 2017-08
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00945815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00945815, "S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00945815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*